MX2019010643A - Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). - Google Patents

Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).

Info

Publication number
MX2019010643A
MX2019010643A MX2019010643A MX2019010643A MX2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A
Authority
MX
Mexico
Prior art keywords
inhibitor
compositions
forms
methods
same
Prior art date
Application number
MX2019010643A
Other languages
English (en)
Inventor
Li Ying
Xu Jean
L Ruchelman Alexander
Jain Uday
Zou Daozhong
Huang Lianfeng
MALONA John
Pabba Chittari
Han Jianxin
MOLTER Kevin
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of MX2019010643A publication Critical patent/MX2019010643A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Abstract

La presente invención se refiere a formas sólidas de un inhibidor de MK2, composiciones de los mismos, y métodos para usar los mismos.
MX2019010643A 2017-03-16 2018-03-15 Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). MX2019010643A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472015P 2017-03-16 2017-03-16
PCT/US2018/022543 WO2018170199A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Publications (1)

Publication Number Publication Date
MX2019010643A true MX2019010643A (es) 2019-10-17

Family

ID=63522534

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010643A MX2019010643A (es) 2017-03-16 2018-03-15 Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).

Country Status (8)

Country Link
US (2) US10882867B2 (es)
EP (1) EP3595658A4 (es)
JP (2) JP2020514360A (es)
CN (1) CN110678178B (es)
AU (1) AU2018236286B2 (es)
CA (1) CA3054823A1 (es)
MX (1) MX2019010643A (es)
WO (1) WO2018170199A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874561T3 (es) 2014-09-17 2021-11-05 Celgene Car Llc Inhibidores de MK2 y usos de los mismos
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
EP3595658A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC FORMS AND COMPOSITIONS OF A MK2 INHIBITOR
AU2018236290B2 (en) 2017-03-16 2022-06-02 Bristol-Myers Squibb Company MK2 inhibitors, synthesis thereof, and intermediates thereto
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715451B2 (en) * 1996-04-12 2000-02-03 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or NEP inhibitors
EP1572693A1 (en) * 2002-12-20 2005-09-14 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶***的调节方法
JP2010533674A (ja) 2007-07-16 2010-10-28 ノバルティス アーゲー Ｍｋ２阻害剤として有用なヘテロ環式化合物
CA2780333C (en) * 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CA2831680C (en) * 2011-04-21 2020-04-21 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
WO2014210319A2 (en) * 2013-06-26 2014-12-31 The Trustees Of Columbia University In The City Of New York Inhibitors of plasmodium falciparum equilibrative nucleoside transporter type 1 as anti-parasitic compounds
US10512651B2 (en) * 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
ES2874561T3 (es) 2014-09-17 2021-11-05 Celgene Car Llc Inhibidores de MK2 y usos de los mismos
BR112017014737A2 (pt) 2015-01-08 2018-01-16 Moerae Matrix Inc formulação de peptídeos inibidores de mk2
EP3595658A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC FORMS AND COMPOSITIONS OF A MK2 INHIBITOR
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
AU2018236290B2 (en) 2017-03-16 2022-06-02 Bristol-Myers Squibb Company MK2 inhibitors, synthesis thereof, and intermediates thereto
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
US20220251105A1 (en) 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
JP2023536427A (ja) 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto

Also Published As

Publication number Publication date
CN110678178A (zh) 2020-01-10
AU2018236286B2 (en) 2022-02-17
EP3595658A4 (en) 2020-11-25
JP2023017840A (ja) 2023-02-07
US10882867B2 (en) 2021-01-05
US20210198276A1 (en) 2021-07-01
EP3595658A1 (en) 2020-01-22
JP2020514360A (ja) 2020-05-21
WO2018170199A1 (en) 2018-09-20
CA3054823A1 (en) 2018-09-20
US11629153B2 (en) 2023-04-18
CN110678178B (zh) 2023-10-03
AU2018236286A1 (en) 2019-09-19
US20200148701A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
IL276082B1 (en) DNA-pk inhibitor compounds, preparations containing them and their uses
MX2019007021A (es) Anticuerpos il-11ra.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
WO2019020602A3 (en) LUMINOPHORE AND COMPOSITION
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2019010642A (es) Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
IL276080A (en) DNA-pk suppressor compounds, UTP-containing preparations and their uses
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.